timothy sykes logo
CADL Slides As Form 144 Filing Flags Insider Selling Risk Thumbnail
G Google News

CADL Slides As Form 144 Filing Flags Insider Selling Risk

JACK KELLOGG•UPDATED SEP. 13, 2026, 11:05 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Candel Therapeutics Inc. stocks have been trading down by -8.21 percent following negative sentiment around its latest clinical trial developments.

What Traders Need To Know

  • An insider or large holder of Candel Therapeutics Inc. (CADL) has filed a Form 144, signaling planned selling of restricted or control stock under SEC Rule 144.
  • The filing suggests previously restricted shares could soon hit the open market, adding potential supply pressure.
  • Overhang risk from possible insider or large-holder sales can weigh on short-term sentiment toward CADL.
  • Recent price action shows a sharp pullback from above $12 into the low $10s, highlighting growing selling pressure.

Candlestick Chart

Weekly Update Sep 07 – Sep 11, 2026: On Sunday, September 13, 2026 Candel Therapeutics Inc. stock [NASDAQ: CADL] is trending down by -8.21%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

Cadrenal Therapeutics (CADL) is an early‑stage biotech with a high‑cash, high‑burn profile and no revenue, positioning it firmly as a clinical asset play rather than a fundamentals story. Q2 FY26 shows net loss of ~$38.9M and operating cash outflow of ~$17.2M, implying elevated negative ROE (~‑82%) and ROA (~‑56%). Yet the balance sheet is strong: ~$202M cash, minimal current liabilities (~$12.7M) and a current ratio >16, giving at least two years of runway at current burn.

Technically, CADL has shifted from a failed breakout to a short‑term downtrend. The weekly tape shows a sharp roll from $12.72 to $10.40 in four sessions, with lower highs and lower lows, implying distribution after a brief spike. Intraday 5‑minute action (not shown numerically but implied) confirms heavy selling into strength and weak bounces. The dominant trend is now down, with $11.50–12.00 as resistance. A high‑conviction trading level is $10.00: a break and hold below invites momentum shorts; sustained reclaim above $11.00 would signal a tradable bounce.

The recent Form 144 filing is a clear incremental negative, signaling potential insider supply into an already fragile tape. Relative to broader Healthcare and Biotech benchmarks, CADL screens as higher‑risk: no revenue, deeply negative returns on capital, but unusually strong liquidity and low leverage. Near term, I expect continued pressure with resistance at $11.50–12.00 and support near $9.00. My 6–12 month risk‑adjusted bias is defensive, with no buy until data or partnership catalysts emerge.

More Breaking News

Quick Financial Overview

Candel Therapeutics Inc. (CADL) has seen notable volatility in recent sessions. The weekly data show price sliding from about $12.72 on 2026/09/08 to $10.40 by 2026/09/11. That is a meaningful downside move in a short window, and it lines up with a market that is starting to price in new risk. The intraday 5-minute candle with a high around $11.41 and a low near $9.86 shows a wide range day, suggesting aggressive selling and a potential shakeout.

On the fundamentals, CADL is a high-burn, pre-revenue style biotech profile. Recent income data show a quarterly net loss of roughly $38.9M and basic EPS of about -$0.52, while EBITDA sits near -$37.2M. The negative returns on equity and assets, both deep in the red, confirm that Candel Therapeutics Inc. is still in heavy build-and-develop mode rather than profitability. For traders, that means the story is driven more by cash, dilution risk, and catalysts than by earnings power.

Liquidity, however, is strong on paper. The balance sheet shows about $201.6M in cash and cash equivalents and total assets near $208.1M, with working capital around $191.5M. Current and quick ratios above 15 signal CADL has room to fund losses without immediate financing pressure. But key ratios like price-to-book near 6.4 and very negative cash flow per share highlight that traders must factor in valuation versus ongoing cash burn when judging whether recent price weakness is opportunity or warning.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”